To prevent recognition and destruction by cytotoxic T cells, cancer cells express ligands that activate T-cell inhibitory receptors, which downregulate their function \[[@B1],[@B2]\]. Antibodies, which target these ligands and expose cancer cells to T-cell recognition, are known as immune checkpoint inhibitors (ICIs) and these agents are now the cornerstone of treatment for metastatic melanoma \[[@B3],[@B4]\]. Among the immune inhibitory pathways that have been identified, the  CTLA-4 and PD-1 pathways have demonstrated significant promise in the clinical setting.

Anti-CTLA-4 antibodies such as ipilimumab and anti-PD-1 antibodies such as pembrolizumab and nivolumab have been approved by the Scottish Medicine Consortium for the treatment of metastatic melanoma since 2014 \[[@B5],[@B6]\]. An ever-growing evidence base demonstrates improved survival and patient outcomes with immunotherapy compared with traditional chemotherapy \[[@B7],[@B8]\]. The majority of adverse events associated with ICIs are mild in nature; however, a proportion of patients do experience grade 3 and 4 toxicities \[[@B9]\]. Rarely, potentially fatal immune-mediated adverse events (IMAEs) such as immune hypophysitis have been observed in patients receiving ICIs \[[@B12],[@B13]\].

Hypophysitis is the inflammation of the pituitary gland, which often leads to irreversible hypopituitarism and can potentially lead to adrenal crisis if left untreated \[[@B14],[@B15]\]. Clinical trial data have suggested rates of hypophysitis up to 17% in patients receiving ipilimumab \[[@B16],[@B17]\]. In comparison, anti-PD1 inhibitors such as pembrolizumab and nivolumab have demonstrated lower rates of hypophysitis -- 0.47% based on a meta-analysis of nine randomized trials \[[@B18]\].

The reason underlying high rates of ipilimumab-mediated hypophysitis is thought to relate to expression of CTLA-4 in the pituitary. Experimental murine studies have demonstrated the expression of CTLA-4 coding RNA and elevated protein levels in pituitary cells. Analysis of a cohort of 20 patients demonstrated that pituitary antibodies, negative at baseline, developed in the seven patients with hypophysitis but not in the 13 patients without, suggesting a potential mechanism for immune-mediated hypophysitis through the development of anti-CTLA4 antibodies causing hypophysitis \[[@B19]\].

In our center, we have noticed a disproportionate increase in the incidence of hypophysitis in our cohort since the inception of these immunotherapeutic agents. Therefore, this study aims to investigate the incidence of all IMAEs with a focus on hypophysitis for patients with metastatic melanoma who received an ICI (ipilimumab, nivolumab and pembrolizumab) in Ninewells Hospital, Dundee, and to compare with published literature.

Methods {#S0001}
=======

All patients with metastatic melanoma who received an ICI (ipilimumab, nivolumab and pembrolizumab) between January 2014 and August 2018 at our center (Ninewells Hospital, Dundee, Scotland) were identified from electronic chemotherapy records. Baseline patient demographic data were collected including age, sex, date of diagnosis, performance status on commencing treatment and treatment received.

In our center, we have two generic databases that store patient\'s medical notes and correspondence (Clinical Portal) as well as Laboratory investigations Integrated Clinical Environment (ICE). Furthermore, the database (Wisdom) contains all day to day progress for patients when they attend radiotherapy, chemotherapy or immunotherapy sessions. The practice nurse/doctor will document the procedure undertaken as well as monitor for any adverse reactions that the patient might have suffered from. The second database (Chemocare) records specifically the type, date and time of administration of immunotherapy, use of adjunct medication as well as any further reports of adverse reaction or ill health.

All four of these databases have been studied and every incidence of possible IMAEs including hypophysitis that had been reported and documented in these records has been included in this study. If present, management and outcome were recorded.

All patients who received ICIs at our center have had a toxicity assessment prior to every cycle, where baseline bloods inclusive of full blood count, urea and electrolytes, liver function test, bone profile, cortisol and thyroid function test were tested. Where there was a clinical indication, a more comprehensive hormone panel was carried out.

In this study, the diagnosis of hypophysitis was made based on the correlation of patient symptoms with the timing of administration of immunotherapy, as well as biochemical and radiological evidence demonstrating the development of hypopituitarism. A thyrotroph deficiency was defined as a low plasma T4 level (\<9.8 pmol/l) with low or inappropriately normal levels of thyroid-stimulating hormone. Corticotroph deficiency was defined as low cortisol levels (\<275 nmol/l) with low or inappropriately normal levels of adrenocorticotropic hormone. Gonadotroph deficiency was defined as low sex steroids (testosterone/estradiol) with inappropriately normal levels of follicle-stimulating hormone and luteinizing hormone levels. Last, lactotroph deficiency is defined as low levels of prolactin (\<6 mU/l). Levels of growth hormone and IGF-1 were also recorded.

Recovery from hypophysitis was defined as a normalization of hormone profile as evidenced by blood tests as well as clinical recovery. Clinical recovery was defined as the patient no longer requiring hormone replacement therapy at the end of the follow-up period.

After collection of data, the study population was stratified into two groups according to treatment type and presence of IMAEs. Progression-free survival was defined as the time from commencing treatment to radiological evidence of progression. Overall survival was defined as the date from treatment commencement to date of death or end of the follow-up period. Grading of adverse events is based on the Common Terminology Criteria for Adverse Events version 5.0 \[[@B20]\].

All data were analyzed using SPSS (IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.). Outcome data from this study were compared using Log-rank analysis to evaluate overall and progression-free survivals between both groups (where p \< 0.05 is considered to be statistically significant). Local ethical approval was obtained prior to collection of data.

Results {#S0002}
=======

Patient demographics {#S0003}
--------------------

A total of 51 patients were identified as having received an ICI during the time period specified and were included in this study. [Table 1](#T1){ref-type="table"} summarizes the characteristics of the study population. The majority of patients were male (74.5%), had a performance status of 0--1 (96%) and had a wild-type *BRAF* status (70.6%). Additionally, 84.3% of our patients have received surgical excision of their primary cutaneous melanoma previously prior to a relapse of their disease, which necessitate the use of immunotherapy. Most patients received no previous systemic treatments (86.3%). Out of the seven patients who received previous systemic treatments, three had received ipilimumab immunotherapy previously, while the remaining four received conventional chemotherapy. To note, it is this center\'s policy to utilize immunotherapy as first line to treat metastatic melanoma, while *BRAF* inhibitors such as dabrafenib are used second line where *BRAF* mutation is positive.

###### **Summary of patient demographics.**

  **Demographic**                                                        **Number**
  ------------------------------------------------- -------------------- --------------
  Age, median (months)                                                   67 ± 14.3
                                                                         
  Duration of follow-up, median (months)                                 7 (1--55)
                                                                         
  Gender:                                           Male                 38 (74.5%)
                                                                         
                                                    Female               13 (25.5%)
                                                                         
  Performance status:                               0                    30 (58.8%)
                                                                         
                                                    1                    19 (37.2%)
                                                                         
                                                    2                    2 (4.0%)
                                                                         
  Cancer type:                                      Cutaneous melanoma   46 (90.2%)
                                                                         
                                                    Ocular melanoma      5 (9.8%)
                                                                         
  Primary cancer resected prior to therapy:         Yes                  43 (84.3%)
                                                                         
                                                    No                   8 (15.7%)
                                                                         
  Number of systemic treatments prior to therapy:   0                    44 (86.3%)
                                                                         
                                                    1                    7 (13.7%)
                                                                         
  *BRAF* mutation status:                           Wild-type            36 (70.6%)
                                                                         
                                                    Positive             6 (11.8%)
                                                                         
                                                    Unknown              9 (17.6%)
                                                                         
  Nature of prior treatment:                        Immunotherapy        3
                                                                         
                                                    Chemotherapy         4
                                                                         
  Type of immunotherapy:                            Ipilimumab           16 (31.4%)
                                                                         
                                                    Nivolumab            2 (3.9%)
                                                                         
                                                    Pembrolizumab        33 (64.7%)
                                                                         
  Mean number of cycles of immunotherapy:           Ipilimumab           3.5 (2--4)
                                                                         
                                                    Nivolumab            3.5 (3--4)
                                                                         
                                                    Pembrolizumab        14.7 (1--50)
                                                                         
  Presence of hypophysitis:                         Yes                  6 (11.7%)
                                                                         
                                                    No                   45 (88.3%)

All patients received their care in Ninewells Cancer Center, Dundee, from initiation of treatment until either the end point of the study or death, median follow-up was 7 months, ranging from 1 to 55 months. Two patients emigrated from the country for end of life care and were lost to follow-up.

Hypophysitis characteristics & management {#S0004}
-----------------------------------------

A total of six patients (11.7%) developed clinically significant hypophysitis during their treatment ([Table 2](#T2){ref-type="table"}). Five of these patients had received ipilimumab (incidence of 31.3% in those who received ipilimumab) and one had received pembrolizumab (incidence of 3.0% in those receiving pembrolizumab). [Table 2](#T2){ref-type="table"} shows the presenting features of each patient with hypophysitis.

###### **Cases of immunotherapy-induced hypophysitis.**

  **Case number**                                 **1**                                         **2**                           **3**                       **4**                                   **5**                      **6**
  ----------------------------------------------- --------------------------------------------- ------------------------------- --------------------------- --------------------------------------- -------------------------- --------------------------------------
  Age                                             70                                            70                              64                          77                                      46                         24
                                                                                                                                                                                                                               
  Gender (M/F)                                    M                                             F                               M                           M                                       M                          F
                                                                                                                                                                                                                               
  Immunotherapy                                   Ipilimumab                                    Ipilimumab                      Ipilimumab                  Ipilimumab                              Ipilimumab                 Pembrolizumab
                                                                                                                                                                                                                               
  Treatment dose (mg/kg)                          3                                             3                               3                           3                                       3                          2
                                                                                                                                                                                                                               
  Number of cycles prior to event                 3                                             4                               4                           2                                       3                          35
                                                                                                                                                                                                                               
  Hormonal defect (time of diagnosis)             Corticotroph, thyrotroph, gonadotroph         Corticotroph, thyrotroph        Corticotroph, gonadotroph   Corticotroph, thyrotroph, gonadotroph   Corticotroph, thyrotroph   Corticotroph, primary hypothyroidism
                                                                                                                                                                                                                               
  MRI findings                                    No abnormalities                              No abnormalities                Not performed               No abnormalities                        Not performed              Not performed
                                                                                                                                                                                                                               
  Symptoms                                        Headache, syncope                             Nausea                          Tiredness                   Headache                                Asymptomatic               Nausea, vomiting
                                                                                                                                                                                                                               
  Dexamethasone dose (mg)                         16                                            8                               8                           10                                      Not given                  Not given
                                                                                                                                                                                                                               
  Recovery from event                             No                                            No                              Yes                         No                                      Yes                        No
                                                                                                                                                                                                                               
  Hormone replacement (at the end of follow-up)   Levothyroxine, testosterone, hydrocortisone   Hydrocortisone, levothyroxine   None                        Hydrocortisone, levothyroxine           None                       Hydrocortisone, levothyroxine
                                                                                                                                                                                                                               
  Additional IMAEs                                None                                          Rash                            None                        Rash                                    None                       None

F: Female; IMAE: Immune mediated adverse event; M: Male; MRI: Magnetic resonance imaging.

Out of the six cases of hypophysitis, four patients required hospitalization, one patient (grade 2) was diagnosed and treated medically as an outpatient, while one patient had grade 1 hypophysitis and was completely asymptomatic (Patient 5). He was only diagnosed as routine blood monitoring has demonstrated mild corticotropin and thyrotropin deficiency.

The patients who developed hypophysitis presented with nonspecific symptoms such as headache, nausea and vomiting. Two patients developed other IMAEs, both of which had a grade 1 rash. Four out of six (66.7%) patients were treated with systemic steroid therapy (Dexamethasone) and steroid treatment duration ranged from 7 to 39 days. Treatment dose of dexamethasone was tailored according to the clinical picture. The remaining two patients were not treated with dexamethasone as one of them was asymptomatic with only mild hormonal deficiencies (Patient 5), while the other (Patient 6) was started on intravenous hydrocortisone upon admission as per advice from the endocrinology team.

All patients demonstrated corticotroph deficiency, four patients required lifelong hydrocortisone replacement while two patients recovered from their hypopituitarism at the end of the follow-up period. Thyroid function derangement was observed in five patients. Four patients demonstrated biochemical evidence of secondary hypothyroidism; however, one patient had concurrent primary hypothyroidism and hypophysitis. Four patients required lifelong levothyroxine replacement, while the remaining patients recovered. Gonadotrophic deficiency was observed in three patients on diagnosis; however, two patients recovered while one patient required testosterone replacement at the end of follow-up. MRI was performed shortly (within 1 week) after presentation in three patients, all of which demonstrated unremarkable findings.

Including the six patients who developed hypophysitis, a further nine (18%) patients ([Table 3](#T3){ref-type="table"}) developed IMAEs, most of which were grade 1--2; three developed primary hypothyroidism, with two requiring levothyroxine replacement. There were six cutaneous reactions (rash and dermatitis) and one incident of grade 3 immune-mediated thrombocytopenia and colitis each.

###### **Immune-mediated adverse events.**

  **Case**   **Immunotherapy**   **Immune-mediated adverse effect**   **Grade**
  ---------- ------------------- ------------------------------------ -----------
  1          Pembrolizumab       Dermatitis in lips                   1
                                                                      
  2          Pembrolizumab       Rash                                 1
                                                                      
  3          Pembrolizumab       Rash                                 1
                                                                      
  4          Pembrolizumab       Hypothyroidism                       1
                                                                      
  5          Pembrolizumab       Hypothyroidism                       2
                                                                      
  6          Pembrolizumab       Hypothyroidism                       2
                                                                      
  7          Pembrolizumab       Thrombocytopenia                     3
                                                                      
  8          Pembrolizumab       Hypophysitis                         3
                                                                      
  9          Ipilimumab          Hypophysitis                         1
                                                                      
  10         Ipilimumab          Rash                                 1
                                                                      
  11         Ipilimumab          Colitis                              2
                                                                      
  12         Ipilimumab          Hypophysitis                         2
                                                                      
  13         Ipilimumab          Hypophysitis                         3
                                                                      
  14         Ipilimumab          Hypophysitis                         3
                                                                      
  15         Ipilimumab          Hypophysitis                         3

Patient outcome data {#S0005}
--------------------

There was no statistically significant difference in overall survival ([Figure 1](#F0001){ref-type="fig"}; 21.6 vs 18.3 months; p = 0.180) between patients who received pembrolizumab and those who received ipilimumab ([Table 4](#T4){ref-type="table"}). However, pembrolizumab provides a better progression-free survival for patients as compared with ipilimumab ([Figure 2](#F0002){ref-type="fig"}; 19.8 vs 12.1 months; p = 0.042).

![**Kaplan--Meier survival curve comparing overall survival of patients who received ipilimumab versus those who received pembrolizumab (p = 0.180).**](mmt-06-13-g1){#F0001}

###### **Characteristics of patients treated with ipilimumab versus pembrolizumab.**

  ---------------------------------------------------------------------------------------------------------
  **Patient Characteristics**          **Ipilimumab (n = 16)**   **Pembrolizumab (n = 33)**   **p-value**
  ------------------------------------ ------------------------- ---------------------------- -------------
  Age                                  62.63                     64.33                        0.691

                                                                                              

  Gender (% male)                      68.75%                    75.76%                       0.624

                                                                                              

  Overall survival (median)            18.3 months;\             21.6 months;\                0.180
                                       95% CI: 9.2--27.4         95% CI: 16.4--26.7           

                                                                                              

  Progression-free survival (median)   12.1 months;\             19.8 months;\                0.042
                                       95% CI: 2.9--21.24        95% CI: 13.9--25.7           
  ---------------------------------------------------------------------------------------------------------

![**Kaplan--Meier survival curve comparing progression-free survival of patients who received ipilimumab versus those who received pembrolizumab (p = 0.042).**](mmt-06-13-g2){#F0002}

Log-rank (Mantel Cox) analysis ([Figures 3](#F0003){ref-type="fig"} & [4](#F0004){ref-type="fig"}) demonstrated a significant difference in overall survival (20.6 vs 11.1 months, p = 0.030) and progression-free survival (16.7 vs 6.38 months; p = 0.041) among patients who develop IMAEs ([Table 5](#T5){ref-type="table"}). There is no observable difference in age or gender distribution seen in both groups. At the end point of follow-up, only two patients (33.33%) recovered their pituitary function and did not require lifelong hormone replacement.

![**Kaplan--Meier survival curve comparing overall survival of patients affected by immune-mediated adverse reaction versus those who did not (p = 0.030).**](mmt-06-13-g3){#F0003}

![**Kaplan--Meier curve comparing progression-free survival of patients affected by immune-mediated adverse reaction versus those who did not (p = 0.041).**](mmt-06-13-g4){#F0004}

###### **Characteristics of patients with and without immune-mediated adverse event.**

  ------------------------------------------------------------------------------------------------------
  **Patient characteristics**          **Affected (n = 15)**   **Not affected (n = 36)**   **p-value**
  ------------------------------------ ----------------------- --------------------------- -------------
  Age                                  64.5                    63.6                        0.846

                                                                                           

  Gender                               73.3%                   75.0%                       0.906

                                                                                           

  Overall survival (median)            20.6 months;\           11.1 months;\               0.030
                                       95% CI: 10.9--30.3      95% CI: 7.8--14.5           

                                                                                           

  Progression-free survival (median)   16.7 months;\           6.38 months;\               0.041
                                       95% CI: 6.9--26.6       95% CI: 3.7--9.1            
  ------------------------------------------------------------------------------------------------------

Discussion {#S0006}
==========

ICIs have revolutionized the treatment of metastatic melanoma. With growing experience and ongoing studies evaluating the efficacy and safety of agents such as ipilimumab and pembrolizumab, the initiation of such treatments can be confidently made. Increasing awareness of the potential side effects has also led to the development of adverse event treatment guidelines \[[@B21],[@B22]\]. This study aimed to quantify objectively the adverse event profile of these agents in the melanoma patient population in the east of Scotland.

The use of ipilimumab to treat melanoma has been discontinued in this cancer center from 2015 due to growing concerns of its toxicity and with the introduction of newer and safer agents such as pembrolizumab and nivolumab. Combination treatment of ipilimumab and nivolumab is also avoided due to toxicity. This study has demonstrated that anti-PD1 inhibitors provide superior patient outcomes in terms of progression-free survival and safety. Multiple Phase III clinical trials have demonstrated improved overall and progression-free survivals for pembrolizumab compared with ipilimumab \[[@B23]\].

In this population, patients taking pembrolizumab developed a lower rate of IMAEs compared with those taking ipilimumab. Moreover, these adverse reactions are often mild and self-limiting, with most patients having only grade 1 and 2 toxicity. This is in contrast to ipilimumab where 42.9% of patients suffered from grade 3 IMAE in contrast to 25% in the pembrolizumab cohort. Three patients (9%) developed hypothyroidism in the pembrolizumab cohort, consistent with the findings of a large systematic review, which found that hypothyroidism is the most common endocrine disorder seen, at a rate of 8% \[[@B27]\].

All six patients who developed hypophysitis demonstrated a variety of hormonal deficiencies, albeit of varying severity. For example, one patient was asymptomatic and made a complete recovery of his pituitary function without need for systemic steroid treatment or hormone replacement. In contrast, four patients required hospitalization, high-dose dexamethasone or intravenous hydrocortisone replacement to effectively manage their symptoms. Ultimately, the majority of these patients required long-term hormone replacement. This observation is consistent with the often unpredictable natural history and severity of hypophysitis that has been described in the current literature \[[@B28],[@B29]\]. This further elucidates the necessity of tailoring the treatment according to the individual patient, with appropriate monitoring to help determine whether to continue with the immunotherapy regime or to switch to other conventional therapies \[[@B30],[@B31]\].

Another interesting finding in this study is the lack of radiological findings in the patient cohort; three out of six patients (50%) who developed hypophysitis received a brain MRI, which failed to demonstrate any significant abnormalities. This is in contrast to the typical findings of an enlarged pituitary gland or infundibulum that is commonly described in other studies investigating this \[[@B32]\]. However, while MRI imaging can aid in reaching the diagnosis, it lacks in specificity particularly when distinguishing hypophysitis and pituitary adenomas or incidentalomas. As such, careful correlation with clinical history and biochemical findings is still necessary \[[@B14]\].

Furthermore, this study population has a lower percentage of *BRAF* mutant melanoma (11.8%) compared with what has been reported in the literature, where a rate of approximately 50% is expected \[[@B35]\]. This finding may represent the variation in the local population leading to a mismatch with other trails population or could be coincidental due to the study\'s small sample size.

With a small sample size (n = 51), it is difficult to draw inferences on the prevalence of hypophysitis from this cohort. However, the study data seem to suggest higher rates of hypophysitis both among patients taking ipilimumab and pembrolizumab. The current literature suggests an incidence of 0--17% for hypophysitis among the ipilimumab patient cohort \[[@B17]\]. To note, while a hypophysitis rate of 0.47% has been quoted in the meta-analysis performed by Costa *et al*. assessing the toxicity profile of pembrolizumab and nivolumab in solid tumors, Wang *et al*. have demonstrated in their study that pembrolizumab causes a hypophysitis rate of \<0.01% specifically in the metastatic melanoma patient cohort \[[@B18],[@B27]\]. To compare, this study\'s cohort demonstrates a rate of 31.3 and 3.0% for ipilimumab and pembrolizumab, respectively.

A possible explanation of the higher rates seen is that there has been an increased vigilance in monitoring patients for IMAEs and a lower threshold to investigate patients presenting with nonspecific symptoms in recent years. Indeed, many earlier studies have attributed a possibility of under-reporting IMAEs due to poor recognition \[[@B36],[@B37]\].

The overall incidence for all grade IMAEs for this cohort is 43.8 and 27.3% for ipilimumab and pembrolizumab, respectively. To compare, two meta-analysis analyzing the adverse effect profile of these two immunotherapy agents reported an incidence of 61 and 26.8% for ipilimumab and pembrolizumab, respectively \[[@B17],[@B27]\]. Our study data broadly match the incidence of reported IMAEs in clinical trials -- although we do recognize that our rates for ipilimumab are lower. This observation is likely associated to a smaller ipilimumab patient cohort due to the shorter duration of use of this agent in our center before it was discontinued, allowing less IMAEs to be recorded.

At the time of treatment, ipilimumab and pembrolizumab were prescribed at a dose of 3 and 2 mg/kg, respectively. We are aware that flat dosing is now standard of care and this is under review at our center. However, this study was not able to elicit a demonstrable difference in cumulative dose between patients who develop hypophysitis and those who did not, as has been shown in other studies \[[@B17],[@B27],[@B35]\]. This is perhaps again attributed to the small sample size.

Interestingly, the data from this study demonstrated statistically and clinically significant improvement in overall and progression-free survivals for patients taking ICIs who develop IMAEs. Though the exact mechanism for this is unknown, multiple studies conducted have also similarly reported improved tumor response rate and increased survival rates with patient who develop IMAEs \[[@B38]\].

Conclusion {#S0007}
==========

This study demonstrates that the incidence of IMAEs and, in particular, hypophysitis in this center\'s population is higher in patients on ipilimumab compared with pembrolizumab. There is an observable increase in incidence of hypophysitis in this cohort as compared with the general study population. The data also support emerging evidence that suggests better overall and progression-free survivals in patients who develop immune-mediated adverse reactions compared with those who did not. With the increased use on ICIs, medical professionals need to be aware of the potential serious adverse events and need to become better at recognizing and managing these specific toxicities.

Future perspective {#S0008}
==================

From this author\'s perspective, there are many new emerging immunotherapies that are currently being trialled at different phases. New immunotherapies and new combinations of immunotherapies/targeted therapy/chemotherapy are now being actively investigated; these will provide clinicians with far more options for treatment as compared with what we currently have now. However, as these treatments are introduced into clinical practice, great care has to be taken to avoid increasing morbidity and mortality in the pursuit of a cure. With the introduction of new treatment regimens and agents, new protocols for monitoring and guidance for managing associated adverse events will be needed to ensure that patients obtain maximal benefit from these treatments. Another area of great improvement that can be anticipated is the development of biomarkers, which will allow us to personalize treatment for our patients where laboratory tests will help us select patients who will respond to certain treatment or help us exclude patients who might develop severe adverse reactions.

###### Summary points

-   Immune checkpoint inhibitors are effective in treating metastatic melanoma, but are known to cause immune-mediated adverse events (IMAEs), which can result in lifelong endocrine complications.

-   Out of 51 patients with metastatic melanoma treated with immune checkpoint inhibitors in Ninewells Hospital, Dundee, a total of 6 patients (11.7%) developed clinically significant hypophysitis, 5 patients had received ipilimumab and 1 had received pembrolizumab.

-   A further nine patients developed other IMAEs; three developed primary hypothyroidism, with a further six cutaneous reactions and one incident of immune-mediated thrombocytopenia and colitis each.

-   There is a greater rate of the development of hypophysitis in our center than reported in published literature.

-   A significant difference in overall survival (20.6 vs 11.1 months, p = 0.03) and progression-free survival (16.7 vs 6.4 months, p = 0.041) was observed among patients who develop IMAEs compared with those who did not.
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